#USA #Cambridge #Longevity #Biophytis #LynxKite

Expanding Horizons in Longevity Therapeutics

Biophytis SA, a prominent name in biotechnology focused on age-related diseases, has announced an exciting expansion of its partnership with LynxKite Technologies. This collaboration is set to turbocharge efforts in artificial intelligence (AI) driven drug discovery, especially in the field of longevity therapeutics. The initiative centers around the MASSIVE project (MAS Receptor Synthetic Innovation Virtual Engineering), which aims to tackle sarcopenia—a degenerative muscle condition that affects a significant segment of the elderly population worldwide.

The Focus of the Collaboration

The primary objective of the MASSIVE project is to develop drug candidates that can activate the Mas receptor (MasR) and provide therapeutic solutions for sarcopenia. This degenerative disease poses a considerable health burden, as it diminishes muscle mass and strength in aging adults. The partnership between Biophytis and LynxKite combines Biophytis' extensive knowledge in pharmacology and experience in drug development with LynxKite’s cutting-edge AI capabilities and computational platforms.

With a decade-long track record of success, the LynxKite team has collaborated with over 100 enterprise clients, including large players like Roche and AstraZeneca. Their expertise in graph-based and generative AI is expected to enhance Biophytis' drug discovery efforts significantly.

Leveraging AI for Drug Discovery

Through this collaboration, LynxKite will integrate AI computational methods into its orchestration platform. This will enable the modeling of the Mas receptor for structure-based drug design, utilizing advanced tools for protein prediction. The project will utilize innovative methods for drug candidate design, allowing for AI-guided molecule generation and predictive filtering to prioritize the most promising drug candidates.

Once potential candidates are identified, they will undergo synthesis and biological testing to assess their activity, safety, and pharmacokinetics. As drug development progresses, the lead candidate will be protected through patent filings to secure its intellectual property rights.

Strategic Significance

Stanislas Veillet, CEO of Biophytis, expressed that the launch of the MASSIVE project marks a critical advancement in their longevity strategy, combining clinical and AI expertise to expedite the discovery of transformative therapies against sarcopenia. Gyorgy Lajtai, CEO of LynxKite, echoed this sentiment, stating their pride in partnering with Biophytis to pioneer innovations in computational longevity, affirming the capability of the LynxKite platform to revolutionize the drug discovery landscape.

This collaboration also aligns perfectly with Singapore's Research, Innovation, and Enterprise (RIE) 2030 plan, aiming to position the country as a leader in research and innovation in the coming decade. By facilitating the development of unique curated datasets and advanced computational methods relevant to longevity, the partnership promises to open new avenues for research and therapeutic breakthroughs.

Conclusion

As this partnership progresses, the combined strengths of Biophytis and LynxKite stand to considerably advance the frontiers of longevity therapeutics. The integration of AI into the drug discovery process not only holds the promise of innovative treatments for age-related diseases but also represents a significant step towards improving quality of life for millions of aging individuals worldwide. Through strategic collaborations like these, the future of medicine continues to evolve, revealing new possibilities for enhancing healthspan and longevity across populations.